THERAPANACEA – Trademark Portfolio
Entity Type: 99
THERAPANACEA holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 42 (Computer & Scientific) — 2 filings in this category. The portfolio also extends into Class 9 (Computers & Electronics) across 4 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include THERAPANACEA and ART-PLAN ADAPTATIVE RADIOTHERAPY TREATMENT. The owner is based in F-75014 Paris.
24 rue du Faubourg Saint-Jacques
F-75014 Paris , FR
Showing of trademarks Trademarks
Trademark Classifications
THERAPANACEA's trademark portfolio spans 4 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Scientific and technological services; industrial analysis and research services
Scientific, nautical, surveying, photographic, cinematographic, optical apparatus and instruments
Medical services; veterinary services; hygienic and beauty care for human beings or animals
Frequently Asked Questions
How many trademarks does THERAPANACEA have?
THERAPANACEA has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.
What trademark classes does THERAPANACEA file in?
THERAPANACEA files trademarks across 4 Nice Classification classes. The most active classes are Class 42 (Computer & Scientific), Class 9 (Computers & Electronics), Class 44 (Medical Services), Class 38 (Telecommunications). Class 42 covers scientific and technological services; industrial analysis and research services.
What are THERAPANACEA's most well-known trademarks?
THERAPANACEA's registered trademark portfolio includes well-known marks such as THERAPANACEA and ART-PLAN ADAPTATIVE RADIOTHERAPY TREATMENT. These are among 2 currently registered trademarks in the portfolio.
What is THERAPANACEA's trademark registration success rate?
THERAPANACEA has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.